Key Insights

Highlights

Success Rate

91% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

7.4%

2 terminated out of 27 trials

Success Rate

90.9%

+4.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

30%

6 of 20 completed with results

Key Signals

6 with results91% success

Data Visualizations

Phase Distribution

27Total
P 1 (23)
P 2 (4)

Trial Status

Completed20
Terminated2
Unknown2
Recruiting2
Active Not Recruiting1

Trial Success Rate

90.9%

Benchmark: 86.5%

Based on 20 completed trials

Clinical Trials (27)

Showing 20 of 20 trials
NCT07226362Phase 1CompletedPrimary

A Study Evaluating the Safety, Tolerability and Pharmacokinetics of ASY202 in Healthy Adults

NCT06331884Phase 1CompletedPrimary

Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics/-Dynamics of AK1967 (Procizumab)

NCT07308041Phase 1Completed

A Study to Investigate the Effect of Linaprazan Glurate on the Pharmacokinetics of Amoxicillin

NCT07098663Phase 2Recruiting

Food Effect, Efficacy and Safety of MKP10241 in Healthy and Obese Adult Participants, With and Without Diabetes

NCT01226316Phase 1Completed

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

NCT06000891Phase 1TerminatedPrimary

A Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570

NCT06453824Phase 1CompletedPrimary

SAD Evaluation of Safety, Tolerability, PK, and PD of MDI-2517 in Healthy Participants

NCT06181760Phase 1CompletedPrimary

A Study to Evaluate the Safety of Fenretinide in Healthy Volunteers

NCT05997641Phase 1Active Not Recruiting

Evaluating the Safety, Tolerability, and Pharmacokinetics of DF-003 in Healthy Subjects

NCT05469854Phase 1Recruiting

A Study to Investigate the Pharmacokinetics and ECG Effects of Linaprazan Glurate

NCT06079541Phase 1UnknownPrimary

Phase 1 Clinical Study of JMKX003142 Tablets

NCT03702231Phase 2CompletedPrimary

Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)

NCT05907382Phase 1UnknownPrimary

Safety, Tolerability of JMKX003002 in Phase 1 Study in Healthy Subjects

NCT05431634Phase 1CompletedPrimary

Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy Participants

NCT05451667Phase 1CompletedPrimary

Single-Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of YJ001 in Healthy Volunteers

NCT05223660Phase 1Completed

A Phase I Pharmacokinetics Study for KT07 Capsule

NCT03685708Phase 2Completed

HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I)

NCT03809052Phase 1CompletedPrimary

A First in Human Study to Evaluate the Safety, Tolerability and PK of GB1211 in Healthy Subjects

NCT03817346Phase 1CompletedPrimary

Study of Ascending Single Oral Dose of GT-002 in Healthy Volunteers

NCT03307512Phase 2TerminatedPrimary

PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD

Scroll to load more

Research Network

Activity Timeline